866-484-8870
|
Expand search form
Menu

Press Releases

36 posts

HALO Diagnostics and Genomic Testing Cooperative Partner to Advance Early Cancer Detection and Precision Diagnostics

HALO Diagnostics and Genomic Testing Cooperative Partner to Advance Early Cancer Detection and Precision Diagnostics

SAN FRANCISCO (PRWEB) JUNE 14, 2022. HALO Diagnostics, a precision diagnostics leader, has joined forces with the Genomic Testing Cooperative (GTC) to offer innovative, personalized testing to its physician network and 1M+ patients served. This solution combines HALO Diagnostics’ clinical ensemble and image-guided therapies with GTC’s genomic profiling of a patient’s DNA / RNA using liquid biopsy and tissue samples. Together, the companies will help patients on every step of their unique healthcare journey – from detection and diagnosis to prognosis and treatment.

Read More

Genomic Testing Cooperative to Reveal “Liquid Trace™” at ASCO, a Liquid Biopsy Test that Combines Cell-Free DNA with Targeted Transcriptome and to Present Data on its Advanced AI for the Diagnosis of Hematologic and Solid Tumors

Irvine, California– June 1, 2022 – Genomic Testing Cooperative, LCA (GTC) announced that it will be presenting at the American Society of Clinical Oncology (ASCO) 2022 annual meeting data showcasing its new innovative approach to liquid biopsy testing that combines both cell-free-DNA (cfDNA) with cell-free RNA (cfRNA), Liquid Trace™. Liquid Trace tests both cfDNA and […]

Read More

Genomic Testing Cooperative and their Cooperative Member Laboratories Expand Hematology Panels to Cover VEXAS Disease and a New Prognostic Biomarker in Myeloproliferative Neoplasms

IRVINE, California, March 2, 2022, Genomic Testing Cooperative, LCA (GTC) announced today that their hematology molecular profiling is expanded to cover analysis of the UBA1 and NFE2 genes. Both genes were recently reported to be clinically important for the diagnosis and treatment of patients with hematologic neoplasms.  Recently described VEXAS (vacuoles, E1 enzyme, X-linked, autoinflammatory, […]

Read More

Genomic Testing Cooperative to Present data at the American Society of Hematology Meeting on its Proprietary Machine Learning Approaches for RNA Transcriptome Data and on the Use of Liquid Biopsy

Irvine, California– December 1, 2021 – Genomic Testing Cooperative, LCA (GTC) announced that it will be presenting at the annual American Society of Hematology (ASH) meeting new data on the use of their proprietary machine learning approaches in the diagnosis of acute graft-versus-host disease (aGVHD) and for the stratifying of patients with diffuse large B-cell […]

Read More

Genomic Testing Cooperative Announces Collaboration with Elevation Oncology to Expand Comprehensive Genomic Testing for NRG1 Fusions Across Solid Tumors in Support of the Phase 2 CRESTONE Study

Irvine, CA – June 30th – Genomic Testing Cooperative, a first-in-class diagnostic company based on a cooperative business model (Co-Op) using the most recent advances in NGS technology, announced today a collaboration with Elevation Oncology to enhance identification of patients with any solid tumor harboring an NRG1 fusion who may be eligible for enrollment in […]

Read More

Genomic Testing Cooperative Completes New York State Approval and Medicare (Palmetto) Coverage for all DNA and RNA Tests Offered for Molecular Profiling of Hematologic and Solid Tumors

Irvine, California– June 23, 2021 – Genomic Testing Cooperative, LCA (GTC) announced that the New York State Clinical Evaluation Program (CLEP) has completed their evaluation and approved all GTC’s Next Generation Sequencing (NGS) profiling tests for hematologic neoplasms and solid tumors.  This includes: -GTC Hematology Profile (177 genes)-GTC Hematology Fusion/Expression (1408 genes)-GTC Hematology PLUS (177 […]

Read More

John Theurer Cancer Center Patients Now Have Access to State-of-the-Art Genomic Profiling Laboratory Technology

New on-site laboratory called Key Genomics is a partnership between Regional Cancer Care Associates (RCCA) and Genomic Testing Cooperative (GTC), provides more precise testing to help improve cancer patient outcomes HACKENSACK, N.J. AND IRVINE, C.A., May 4, 2021 —Patients at John Theurer Cancer Center at Hackensack University Medical Center now have access to state-of-the-art genomic […]

Read More

Hackensack Meridian Health Launches Anthology Diagnostics Laboratories for State-of-the-Art Lab Genomic Profiling of Cancers

anthology diagnostics

EDISON, N.J. AND IRVINE, C.A. (March 16, 2021) — Hackensack Meridian Health and Genomic Testing Cooperative (GTC) in Irvine, California, have teamed up to establish the first-of-its-kind genomic profiling laboratory called Anthology Diagnostics, to generate more personalized, precise, and real-time insights for cancer patients, oncologists and hospitals.   The reference laboratory located at Hackensack Meridian JFK University Medical […]

Read More

Genomic Testing Cooperative Establishes a Program to Address Cancer Disparity by Offering Molecular Profiling to Minority Patients without Adequate Insurance Coverage and Facilitating Access to Precision Medicine and Enrollment in Clinical Trials

disparity

Irvine, California – February 2, 2021 – Genomic Testing Cooperative, LCA (GTC) announced today that they are establishing a program offering comprehensive molecular profiling (DNA+RNA) testing to patients with cancer who are affected by cancer disparity and unable to pay due to lack of insurance or lack of coverage of this type of testing.  Ethnic and […]

Read More